Pathophysiology of fistula formation in Crohn's disease
- PMID: 25133023
- PMCID: PMC4133520
- DOI: 10.4291/wjgp.v5.i3.205
Pathophysiology of fistula formation in Crohn's disease
Abstract
Fistulae represent an important complication in patient suffering from Crohn's disease (CD). Cumulative incidence of fistula formation in CD patients is 17%-50% and about one third of patients suffer from recurring fistulae formation. Medical treatment options often fail and also surgery frequently is not successful. Available data indicate that CD-associated fistulae originate from an epithelial defect that may be caused by ongoing inflammation. Having undergone epithelial to mesenchymal transition (EMT), intestinal epithelial cells (IEC) penetrate into deeper layers of the mucosa and the gut wall causing localized tissue damage formation of a tube like structure and finally a connection to other organs or the body surface. EMT of IEC may be initially aimed to improve wound repair mechanisms since "conventional" wound healing mechanisms, such as migration of fibroblasts, are impaired in CD patients. EMT also enhances activation of matrix remodelling enzymes such as matrix metalloproteinase (MMP)-3 and MMP-9 causing further tissue damage and inflammation. Finally, soluble mediators like TNF and interleukin-13 further induce their own expression in an autocrine manner and enhance expression of molecules associated with cell invasiveness aggravating the process. Additionally, pathogen-associated molecular patterns also seem to play a role for induction of EMT and fistula development. Though current knowledge suggests a number of therapeutic options, new and more effective therapeutic approaches are urgently needed for patients suffering from CD-associated fistulae. A better understanding of the pathophysiology of fistula formation, however, is a prerequisite for the development of more efficacious medical anti-fistula treatments.
Keywords: Crohn’s disease; Epithelial to mesenchymal transition; Fistula; Interleukin-13; Transforming growth factor; Tumor necrosis factor.
Figures

Similar articles
-
A role for tumor necrosis factor and bacterial antigens in the pathogenesis of Crohn's disease-associated fistulae.Inflamm Bowel Dis. 2013 Dec;19(13):2878-87. doi: 10.1097/01.MIB.0000435760.82705.23. Inflamm Bowel Dis. 2013. PMID: 24189042
-
The role for dickkopf-homolog-1 in the pathogenesis of Crohn's disease-associated fistulae.PLoS One. 2013 Nov 8;8(11):e78882. doi: 10.1371/journal.pone.0078882. eCollection 2013. PLoS One. 2013. PMID: 24250816 Free PMC article.
-
[Perianal fistulas in CED: from mouse model to clinic].Ther Umsch. 2019 Jan;75(5):287-294. doi: 10.1024/0040-5930/a001000. Ther Umsch. 2019. PMID: 30700244 Review. German.
-
Interleukin-13 and transforming growth factor β synergise in the pathogenesis of human intestinal fistulae.Gut. 2013 Jan;62(1):63-72. doi: 10.1136/gutjnl-2011-300498. Epub 2012 Jan 27. Gut. 2013. PMID: 22287592
-
Pathogenesis of Fistulating Crohn's Disease: A Review.Cell Mol Gastroenterol Hepatol. 2023;15(1):1-11. doi: 10.1016/j.jcmgh.2022.09.011. Epub 2022 Sep 29. Cell Mol Gastroenterol Hepatol. 2023. PMID: 36184031 Free PMC article. Review.
Cited by
-
Persistent Inflammation of the Rectum in Perianal Fistulizing Crohn's Disease Is Associated With Goblet Cell Function.Gastro Hep Adv. 2023 Sep 9;3(1):131-133. doi: 10.1016/j.gastha.2023.09.002. eCollection 2024. Gastro Hep Adv. 2023. PMID: 39132177 Free PMC article. Review. No abstract available.
-
Eribulin Does Not Prevent Epithelial-to-Mesenchymal Transition in HT-29 Intestinal Epithelial Cells.Inflamm Intest Dis. 2018 Jul;2(4):211-218. doi: 10.1159/000490052. Epub 2018 Jul 10. Inflamm Intest Dis. 2018. PMID: 30221148 Free PMC article.
-
Prospective randomised controlled trial of adults with perianal fistulising Crohn's disease and optimised therapeutic infliximab levels: PROACTIVE trial study protocol.BMJ Open. 2021 Jul 1;11(7):e043921. doi: 10.1136/bmjopen-2020-043921. BMJ Open. 2021. PMID: 34210720 Free PMC article.
-
Genetic coding variant in complement factor B (CFB) is associated with increased risk for perianal Crohn's disease and leads to impaired CFB cleavage and phagocytosis.Gut. 2023 Nov;72(11):2068-2080. doi: 10.1136/gutjnl-2023-329689. Epub 2023 Apr 20. Gut. 2023. PMID: 37080587 Free PMC article.
-
Surgical Management of Small Bowel Crohn's Disease.Front Surg. 2022 Apr 15;9:759668. doi: 10.3389/fsurg.2022.759668. eCollection 2022. Front Surg. 2022. PMID: 35495760 Free PMC article. Review.
References
-
- Schwartz DA, Loftus EV, Tremaine WJ, Panaccione R, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of fistulizing Crohn’s disease in Olmsted County, Minnesota. Gastroenterology. 2002;122:875–880. - PubMed
-
- Solomon MJ. Fistulae and abscesses in symptomatic perianal Crohn’s disease. Int J Colorectal Dis. 1996;11:222–226. - PubMed
-
- Nielsen OH, Rogler G, Hahnloser D, Thomsen OØ. Diagnosis and management of fistulizing Crohn‘s disease. Nat Clin Pract Gastroenterol Hepatol. 2009;6:92–106. - PubMed
-
- Loftus EV, Schoenfeld P, Sandborn WJ. The epidemiology and natural history of Crohn’s disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther. 2002;16:51–60. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous